



## BRP – Recall of spironolactone

- On January 29, 2021, [BRP announced](#) a voluntary, consumer level recall of four lots of [spironolactone](#) tablets due to potential mislabeled package displaying incorrect strength information.
- The recalled lots are listed below:

Product Description	NDC#	Lot# (Expiration Date)
Spironolactone 25 mg tablets	63629106401	148969 (7/31/2022)
	63629106402	148791 (7/31/2022)
	63629106403	148991 (7/31/2022)
Spironolactone 50 mg tablets	63629106701	148992 (5/31/2022)

- Spironolactone tablets are indicated for the treatment of heart failure, hypertension, edema associated with hepatic cirrhosis or nephrotic syndrome, and primary hyperaldosteronism.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the recalled spironolactone.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact BRP by phone at **1-877-855-0882** or by email at [cs@brppharma.com](mailto:cs@brppharma.com) for further information regarding this recall.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.